New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
08:56 EDTBIIBBiogen January weekly volatility elevated at 74 into Q4 and revenue outlook
Biogen January weekly call option implied volatility is at 74, February is at 40, March is at 38, April is at 37; compared to its 26-week average of 34 according to Track Data, suggesting large price movement into the expected release of Q4 results on January 29.
News For BIIB From The Last 14 Days
Check below for free stories on BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
08:34 EDTBIIBPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
April 14, 2014
09:46 EDTBIIBBiogen hugs support at critical technical juncture, levels to watch
Subscribe for More Information
07:33 EDTBIIBBiogen to present Plegridy, Tecfidera data at AAN annual meeting
Subscribe for More Information
April 11, 2014
10:15 EDTBIIBBiogen heads for test of $280 area
The shares are heading lower after an early bounce attempt and are now just above the session low at $280.13. As noted yesterday, a break below $280 would confirm topping in the shares. Support below $280 is at $273.45. Resistance is at $285.
April 10, 2014
15:13 EDTBIIBBiogen tumbles, nearing important test of support
Subscribe for More Information
09:00 EDTBIIBBiogen May volatility elevated at 43 into Q1 and revenue outlook
Subscribe for More Information
07:31 EDTBIIBBiogen names Adam Koppel as SVP, Chief Strategy Officer
Subscribe for More Information
07:08 EDTBIIBBiogen announces positive top-line efficacy, safety results from Phase 3 trial
Biogen Idec and Swedish Orphan Biovitrum AB released positive top-line results of the Kids A-LONG Phase 3 clinical study that evaluated the safety and efficacy of Eloctate, an investigational recombinant factor VIII Fc fusion protein product candidate, in children with severe haemophilia A. Eloctate was generally well-tolerated and no inhibitors were detected. Efficacy analyses showed twice-weekly prophylactic dosing with Eloctate maintained low bleeding rates in children.
April 8, 2014
07:22 EDTBIIBCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use